Inventiva (IVA) Non Operating Income (2020 - 2021)
Inventiva's (IVA) quarterly Non Operating Income came in at -$735809.8 in Q2 2021, down 66703.13% year-on-year from N/an in Q2 2020, and down 142.51% quarter-over-quarter from $1.7 million in Q1 2021.
Inventiva (IVA) Non Operating Income (2020 - 2021) Analysis & Trends
Inventiva's Non Operating Income history runs 2 years deep, the most recent figure standing at -$735809.8 for Q2 2021.
- On a quarterly basis, Non Operating Income fell 66703.13% year-over-year to -$735809.8 in Q2 2021; TTM through Jun 2021 was -$3.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$247.7 million, down 169.48% from the prior year.
- Non Operating Income eased to -$735809.8 in Q2 2021 per IVA's latest filing, from $1.7 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.7 million in Q1 2021 and bottomed at -$4.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -735,809.85 |
| Mar 31, 2021 | 1.73 Mn |
| Dec 31, 2020 | -4.65 Mn |
| Jun 30, 2020 | -1,101.46 |
| Mar 31, 2020 | 7,727.57 |